Why the IDT Australia (ASX:IDT) share price is crashing 37% lower today

IDT shares are being hammered today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDT Australia Limited (ASX: IDT) share price is crashing down to Earth on Thursday morning.

At the time of writing, the pharmaceutical manufacturing company's shares are down 37% to 30 cents.

A woman screams and holds her hands up in frustration.

Image source: Getty Images

Why is the IDT Australia share price crashing today?

Investors have been selling down the IDT Australia share price today after it was dealt a bitter blow.

Earlier this year, the company announced that it successfully manufactured an mRNA drug product. This made IDT the first in Australia to manufacture a cGMP mRNA drug product.

In light of this, there were hopes that this would support its Australian Government Approach To Market submission to establish an onshore mRNA manufacturing capability (ATM).

However, this morning the Australian Government has confirmed that IDT's ATM submission has not been selected to progress to the next stage of the process.

IDT's CEO, Dr David Sparling, commented: "Whilst we are disappointed in the outcome of the ATM process, IDT has developed and progressed several alternative strategic options. The Company has successfully delivered on the Monash Institute of Pharmaceutical Sciences (MIPS) COVID-19 mRNA receptor binding domain vaccine candidate project, being Australia's first locally manufactured cGMP mRNA finished product and clearly showcases IDT's manufacturing capabilities in this regard."

What's next?

Dr Sparling notes that the company remains in the running for the Manufacturing Collaboration Stream Grant Opportunity.

"IDT is now sterile licenced and is maintaining its sterile facilities in a state of readiness to accept COVID-19 vaccine content at the Government's discretion. The Company is also waiting to receive feedback on its submission to the Australian Government's $800m Modern Manufacturing Initiative (MMI) Manufacturing Collaboration Stream Grant Opportunity," Dr Sparling added.

Positively, the company also stressed that the proposal is unaffected by the outcome of the ATM process. It will provide a market update if and when additional information comes to hand.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor checking patient's spine x-ray image.
Healthcare Shares

Why is this ASX biotech charging more than 10% higher?

A compelling patient account makes for interesting reading.

Read more »

A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech, and health companies.
Healthcare Shares

Why this ASX biotech stock is soaring 30% today

Share price flies higher on European drug approval breakthrough.

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

Another CSL blow: Why this beaten-up ASX giant is sliding again

This ASX blue chip is still trying to rebuild trust.

Read more »

Green arrow going up on a stock market chart, symbolising a rising share price.
Share Market News

Up 230% in 5 years! Is this still a top Australian stock to buy?

Could this business keep generating strong returns?

Read more »

Two women look happily at an X-ray of a person's chest with one giving the thumbs up sign.
Healthcare Shares

Up 23% this year, why Ramsay Health Care shares are tipped for more 'compelling upside'

A leading fund manager forecasts more outperformance from Ramsay Health Care’s rebounding share price.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

This ASX 200 stock has soared 1,800%. Is there more to come?

A new approval has this ASX 200 healthcare stock climbing again.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

Once untouchable, now unloved: What's up with CSL shares?

CSL's stunning fall has investors questioning its comeback prospects.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Pro Medicus just struck a revolutionary AI cardiology deal. Here's why that matters

This small-ticket transaction matters far more than its size suggests.

Read more »